81,377 results match your criteria Acute Myelogenous Leukemia


Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.

Blood Adv 2020 Jul;4(13):3109-3122

Division of Pediatric Oncology, Department of Pediatrics, Center for Childhood Cancer Research and.

Understanding mechanisms of cooperation between oncogenes is critical for the development of novel therapies and rational combinations. Acute myeloid leukemia (AML) cells with KMT2A-fusions and KMT2A partial tandem duplications (KMT2APTD) are known to depend on the histone methyltransferase DOT1L, which methylates histone 3 lysine 79 (H3K79). About 30% of KMT2APTD AMLs carry mutations in IDH1/2 (mIDH1/2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001922DOI Listing

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.

Blood Adv 2020 Jul;4(13):3063-3071

Guy's and St Thomas' National Health Service Foundation Trust, Guy's Hospital, London, United Kingdom.

The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). The primary objective of phase 1b was to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and phase 2 was to assess spleen volume reduction at weeks 24 and 48. Fifty patients were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001212DOI Listing

Design of an integrated model for diagnosis and classification of pediatric acute leukemia using machine learning.

Proc Inst Mech Eng H 2020 Jul 7:954411920938567. Epub 2020 Jul 7.

School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Applying artificial intelligence techniques for diagnosing diseases in hospitals often provides advanced medical services to patients such as the diagnosis of leukemia. On the other hand, surgery and bone marrow sampling, especially in the diagnosis of childhood leukemia, are even more complex and difficult, resulting in increased human error and procedure time decreased patient satisfaction and increased costs. This study investigates the use of neuro-fuzzy and group method of data handling, for the diagnosis of acute leukemia in children based on the complete blood count test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0954411920938567DOI Listing

Dying patients with COVID-19: What should Hospital Palliative Care Teams (HPCTs) be prepared for?

Authors:
Johanna Anneser

Palliat Support Care 2020 Jun 23:1-3. Epub 2020 Jun 23.

Palliative Care Team, Department of Psychosomatic Medicine and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.

Objective: The COVID-19 pandemic is a care crisis of unknown duration which has seemingly not yet reached its peak in many countries. A significant number of elderly and frail people and those with underlying serious illness will continue to develop severe forms of the COVID-19 infection. Most of them are not eligible for intensive care treatment but can still expect palliative care - in many cases provided by a Hospital Palliative Care Team (HPCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1478951520000450DOI Listing

Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

Int J Mol Sci 2020 Jun 30;21(13). Epub 2020 Jun 30.

Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, P.le A. Stefani 1, 37126 Verona, Italy.

Inherited bone marrow failure syndromes (IBMFS) are a group of cancer-prone genetic diseases characterized by hypocellular bone marrow with impairment in one or more hematopoietic lineages. The pathogenesis of IBMFS involves mutations in several genes which encode for proteins involved in DNA repair, telomere biology and ribosome biogenesis. The classical IBMFS include Shwachman-Diamond syndrome (SDS), Diamond-Blackfan anemia (DBA), Fanconi anemia (FA), dyskeratosis congenita (DC), and severe congenital neutropenia (SCN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134672DOI Listing

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling.

Cancers (Basel) 2020 Jun 30;12(7). Epub 2020 Jun 30.

Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

Given the proven importance of the CXCL12/CXCR4 axis in the stroma-acute myeloid leukemia (AML) interactions and the rapid emergence of resistance to FLT3 inhibitors, we investigated the efficacy and safety of a novel CXCR4 inhibitor, LY2510924, in combination with FLT3 inhibitors in preclinical models of AML with FLT3-ITD mutations (FLT3-ITD-AML). Quizartinib, a potent FLT3 inhibitor, induced apoptosis in FLT3-ITD-AML, while LY2510924 blocked surface CXCR4 without inducing apoptosis. LY2510924 significantly reversed stroma-mediated resistance against quizartinib mainly through the MAPK pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071737DOI Listing

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.

Cancers (Basel) 2020 Jun 30;12(7). Epub 2020 Jun 30.

Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) interfere with cellular metabolism contributing to oncogenesis. Mutations of IDH2 at R140 and R172 residues are observed in 20% of acute myeloid leukemias (AML), and the availability of the IDH2 inhibitor Enasidenib made IDH2 mutational screening a clinical need. The aim of this study was to set a new quantitative polymerase chain reaction (PCR) technique, the drop-off digital droplet PCR (drop-off ddPCR), as a sensitive and accurate tool for detecting IDH2 mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071738DOI Listing

Myeloid sarcoma of the nasal cavity in a 15-month-old child: A case report.

Medicine (Baltimore) 2020 Jul;99(27):e21119

Department of Otolaryngology-Head and Neck Surgery.

Introduction: Myeloid sarcoma (MS) is a rare tumor mass. It may occur at any extramedullary anatomic sites but is uncommon in the sinonasal location.MS commonly presents concurrently with acute myeloid leukemia (AML), but it may predate AML over several months or years, named isolated MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000021119DOI Listing

Association between the Wilms tumor-1 rs16754 polymorphism and acute myeloid leukemia: A MOOSE-compliant meta-analysis.

Medicine (Baltimore) 2020 Jul;99(27):e20713

Department of Burn Surgery, The First Hospital of Jilin University, Changchun, China.

The Wilms tumor-1 (WT1) protein is an important regulator of malignant hematopoiesis and has been implicated in the pathogenesis of acute myeloid leukemia (AML). Recently special attention has been paid to the relationship of the WT1 single nucleotide polymorphism (SNP) rs16754 with AML risk and outcome, but the conflicting results made it difficult to draw definitive conclusions. In the present study, we systematically reviewed the literature and performed a meta-analysis of existing evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020713DOI Listing

Genome-wide DNA methylome analysis reveals methylation subtypes with different clinical outcomes for acute myeloid leukemia patients.

Cancer Med 2020 Jul 6. Epub 2020 Jul 6.

Department of Hematology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.

Leukemia is the second common blood cancer after lymphoma, and its incidence rate has an increasing trend in recent years. Acute myeloid leukemia (AML) is one of the prevalent forms of leukemia. Although previous studies have investigated the methylation profile for AML patients, the AML methylation subtypes based on the genome-wide methylome are still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3291DOI Listing

Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.

Am J Hematol 2020 Jul 6. Epub 2020 Jul 6.

Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA.

FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML), and their presence confers adverse risk. FLT3-mutated (FLT3m) AML is a challenging leukemia to manage, particularly in older and unfit patients as well as patients with relapsed/refractory (r/r) disease. We retrospectively analyzed the outcomes of 50 FLT3m AML patients (17 treatment-naïve, 33 r/r) treated with venetoclax (VEN) and hypomethylating agents (HMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25929DOI Listing

Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.

Oncol Rep 2020 Jul 22;44(1):273-282. Epub 2020 Apr 22.

Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, P.R. China.

Acute myeloid leukemia (AML) is a highly aggressive disease with high mortality and recurrence rates, for which novel therapeutic approaches are required. Hybrid anticancer agents with dual effects have been reported to possess therapeutic potential to treat AML. However, the efficacy and underlying toxicity of these hybrids in combination with other agents remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2020.7591DOI Listing

Acute Myeloid Leukemia in Qatar (2010-2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes.

Front Genet 2020 17;11:553. Epub 2020 Jun 17.

Center of Excellence in Bionanoscience Research and Genomics and Biotechnology Section and Research Group, Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.

The current study retrospectively evaluated cytogenetic profiles, various prognostic factors, and survival outcomes in 128 acute myeloid leukemia (AML) patients (14 ≤ age ≤ 70 years) admitted to the National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, between January 2010 and December 2016. The median age at diagnosis was 43 years, and 80% were less than 60 years old; 75% of patients were male. Cytogenetic analysis was integrated into the World Health Organization 2008 classification and showed that the percentages of normal and abnormal karyotypes were similar, accounting for 48. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2020.00553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313235PMC

[Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].

Rinsho Ketsueki 2020 ;61(6):687-696

Cancer Science Institute of Singapore, National University of Singapore.

The RUNX1 gene is a critical transcription factor for the generation and maintenance of hematopoietic stem cells. RUNX1 is also one of the most frequently mutated gene in sporadic leukemias. Heterozygous loss-of-function mutations of the RUNX1 gene in the germline cause a rare autosomal dominant disorder called familial platelet disorder with propensity to acute myelogenous leukemia (FPD/AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.687DOI Listing
January 2020

[Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].

Authors:
Hiroshi Moritake

Rinsho Ketsueki 2020 ;61(6):665-672

Division of Pediatrics, Department of Developmental and Urological Reproductive Medicine, Faculty of Medicine, University of Miyazaki.

In Japan, acute myeloid leukemia (AML) accounts for approximately 25% of all pediatric leukemias, with approximately 150 cases of newly diagnosed AML occurring annually. Approximately 10% of patients have primary induction failure and 30% of patients, who initially achieve remission in primary treatments, subsequently relapse. Novel treatment modalities need to be developed to further improve the prognosis of pediatric AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.665DOI Listing
January 2020

E3 ligase SCF ubiquitinates and degrades tumor suppressor C/EBPα in acute myeloid leukemia.

Life Sci 2020 Jul 2:118041. Epub 2020 Jul 2.

Room No. LSS008, Division of Cancer Biology, CSIR-Central Drug Research Institute, CDRI Sector-10, Jankipuram Extension, Lucknow, 226031, UP, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India. Electronic address:

Aim: Transcription factor CCAAT/Enhancer binding protein alpha (C/EBPα) is a key regulator of myeloid differentiation, granulopoiesis in particular. Although CEBPA mutations are found in more than 10% in AML, functional inhibition of C/EBPα protein is also widely observed in AML. Here, we sought to examine if SKP2, an aberrantly enhanced E3 ubiquitin ligase in primary AMLs inhibits C/EBPα stability to induce differentiation block. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2020.118041DOI Listing
July 2020
2.702 Impact Factor

A systematic approach on the frequency of cleft lip/palate in pediatric patients with leukemia.

J Stomatol Oral Maxillofac Surg 2020 Jul 1. Epub 2020 Jul 1.

Department of Maxillofacial Surgery and Implantology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Purpose: The purpose of this study was to reveal the frequency between cleft lip/palate and leukemia in pediatric patients by a systematic analysis of the current literature.

Materials And Methods: Electronic search on three database (PubMed, Web of Science, Cochrane) was carried out  using the following keywords: cleft lip; cleft palate; facial cleft; oral cleft; orofacial cleft; leukemia; acute myeloid leukemia; acute lymphocytic leukemia; lymphoma. Studies published until March 2020 reporting an association between leukemia and cleft lip/palate(CL/P) were included in our research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jormas.2020.06.012DOI Listing

TRIB3 destabilizes tumor suppressor PPARα expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.

Life Sci 2020 Jul 1;257:118021. Epub 2020 Jul 1.

Central Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing 402160, China; Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China. Electronic address:

Aims: Tribbles homolog 3 (TRIB3) is emerging as a multifunctional oncoprotein associated with various cellular events in different tumors. However, the regulatory mechanism of TRIB3 in acute myeloid leukemia (AML) remains unknown. This study aims to investigate the molecular mechanisms and uncover the functions of TRIB3 in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2020.118021DOI Listing

Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04168-2DOI Listing

Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia.

Ann Hematol 2020 Jul 3. Epub 2020 Jul 3.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307, Dresden, Germany.

Resistant disease is still a main obstacle in acute myeloid leukemia (AML) treatment. Therefore, individual genetic variations affecting therapy response are gaining increasing importance. Both SNPs and ABC transporter genes could already be associated with drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04163-7DOI Listing

A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

J Mol Med (Berl) 2020 Jul 3. Epub 2020 Jul 3.

Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida, Uttar Pradesh, 201313, India.

Acute myeloid leukemia (AML) is an extremely heterogeneous disease defined by the clonal growth of myeloblasts/promyelocytes not only in the bone marrow but also in peripheral blood and/or tissues. Gene mutations and chromosomal abnormalities are usually associated with aberrant proliferation and/or block in the normal differentiation of hematopoietic cells. So far, the combination of cytogenetic profiling and molecular and gene mutation analyses remains an essential tool for the classification, diagnosis, prognosis, and treatment for AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-020-01944-5DOI Listing

Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion.

Nat Commun 2020 Jul 3;11(1):3339. Epub 2020 Jul 3.

Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.

Chromosomal NUP98-PHF23 translocation is associated with an aggressive form of acute myeloid leukemia (AML) and poor survival rate. Here, we report the molecular mechanisms by which NUP98-PHF23 recognizes the histone mark H3K4me3 and is inhibited by small molecule compounds, including disulfiram that directly targets the PHD finger of PHF23 (PHF23PHD). Our data support a critical role for the PHD fingers of NUP98-PHF23, and related NUP98-KDM5A and NUP98-BPTF fusions in driving leukemogenesis, and demonstrate that blocking this interaction in NUP98-PHF23 expressing AML cells leads to cell death through necrotic and late apoptosis pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-17098-4DOI Listing

Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes.

Anticancer Res 2020 Jul;40(7):3883-3888

IGF Oncology, LLC, Saint Paul, MN, U.S.A.

Background/aim: The insulin-like growth factor type 1 receptor (IGF-1R) is overexpressed in myelodysplastic syndrome (MDS) cells, and 765IGF-Methotrexate (IGF-MTX) is a conjugate of methotrexate and a variant of insulin-like growth factor-1 (IGF-1) designed to selectively target cancer cells through binding to IGF-1R. The aim of this study was to determine whether IGF-MTX would be effective to treat MDS.

Patients And Methods: In this phase I clinical trial, two patients with high grade MDS or oligoblastic acute myeloid leukemia (O-AML) that had failed standard therapy were treated with IGF-MTX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14378DOI Listing

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

J Hematol Oncol 2020 Jul 3;13(1):87. Epub 2020 Jul 3.

Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France.

Background: Graft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte globulin or anti-T-lymphocyte globulin (ATG) should be used for GVHD prophylaxis in patients undergoing matched-unrelated donor (MUD) allo-HSCT. More recently, using post-transplant cyclophosphamide (PTCY) in the haploidentical setting has resulted in low incidences of both acute (aGVHD) and chronic GVHD (cGVHD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00923-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333262PMC

Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome.

Cancer Genet 2020 Jun 14;245:42-48. Epub 2020 Jun 14.

Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Abramson Research Center, Room 716D, 3615 Civic Center Blvd., Philadelphia, PA 19104, United States; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address:

Gain of function variants in SAMD9 cause MIRAGE syndrome, a rare Mendelian disorder that results in myeloid dysplastic syndrome (MDS), poor immune response, restricted growth, adrenal insufficiency, ambiguous genitalia, feeding difficulties and most often significantly reduced lifespan. In this study, we describe histomorphologic and genetic changes occurring in serial bone marrow measurements in a patient with MIRAGE syndrome and untreated MDS of 9 years. Histomorphological analysis during childhood showed progressive hypocellularity with erythroid and megakaryocytic dysplasia and cytogenetic testing demonstrated monosomy 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2020.06.002DOI Listing

Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions.

Cell Syst 2020 Jun 24. Epub 2020 Jun 24.

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

A persistent puzzle in cancer biology is how mutations, which neither alter growth signaling pathways nor directly interfere with drug mechanism, can still recur and persist in tumors. One example is the mutation of the DNA demethylase tet methylcytosine dioxygenase 2 (TET2) in acute myeloid leukemias (AMLs) that frequently persists from diagnosis through remission and relapse, but whose fitness advantage in chemotherapy is unclear. Here, we use isogenic human AML cell lines to show that TET2 loss of function alters the dynamics of transitions between differentiated and stem-like states. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2020.06.003DOI Listing

Rubbing Out Leukemia Stem Cells by Erasing the Eraser.

Cell Stem Cell 2020 Jul;27(1):3-5

Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address:

In this issue of Cell Stem Cell, Shen et al. (2020) and Wang et al. (2020) independently identify the essential function of mA demethylase ALKBH5 in maintaining myeloid leukemia stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2020.06.009DOI Listing

Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.

Cancer Sci 2020 Jul 3. Epub 2020 Jul 3.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Although next-generation sequencing-based panel testing is well-practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical-sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical-sequencing assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14552DOI Listing

Inherited Thrombocytopenia Caused by Germline Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome.

J Investig Med High Impact Case Rep 2020 Jan-Dec;8:2324709620938941

Hematology-Oncology Leukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Thrombocytopenia 2 (THC2) is an autosomal dominant disorder characterized by ankyrin repeat domain 26 mutation and moderate thrombocytopenia. THC2 exposes patients to a low risk of bleeding and an increased likelihood of myelodysplastic syndrome/acute myeloid leukemia. Germline evaluation for a genetic disorder should be considered when a patient presents with isolated thrombocytopenia and associated dysmegakaryopoiesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709620938941DOI Listing

Depleting interferon regulatory factor-1(IRF-1) with CRISPR/Cas9 attenuates inducible oxidative metabolism without affecting RA-induced differentiation in HL-60 human AML cells.

FASEB Bioadv 2020 Jun 22;2(6):354-364. Epub 2020 May 22.

Department of Biomedical Sciences Cornell University Ithaca NY USA.

The known collaboration between all-transretinoic acid and interferon motivates this study of the dependence of RA-induced leukemic cell differentiation on interferon regulatory factor-1 (IRF-1), a transcription factor that is the main mediator of interferon effects. In the HL-60 acute myeloid leukemia (AML) model that represents a rare RA-responsive subtype of AML, IRF-1 is not expressed until RA induces its prominent expression, and ectopic IRF-1 expression enhances RA-induced differentiation, motivating interest in how IRF-1 is putatively needed for RA response. Accordingly, we created CRISPR/Cas9-mediated IRF-1 knockout HL-60 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fba.2020-00004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325585PMC

Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia.

Ann Transl Med 2020 Jun;8(11):678

Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Background: Glutathione peroxidases (GPXs) are an enzyme family with peroxidase activity. Abnormal GPX expression is associated with carcinogenesis. However, the potential role of the GPX gene family in acute myeloid leukemia (AML) remains to be comprehensively examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm-20-3296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327321PMC

Bone marrow metastasis of glioblastoma multiforme mimicking acute myeloid leukemia.

Oxf Med Case Reports 2020 Jun 25;2020(6):omaa040. Epub 2020 Jun 25.

Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

A 46-year-old female patient with glioblastoma multiforme (GBM), IDH wild type developed severe pancytopenia 5 months after postoperative chemoradiotherapy. Bone marrow aspirate showed normocellular marrow with 70.0% abnormal cells, which suggested the possibility of acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omaa040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315933PMC

CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.

Haematologica 2020 Jul 2. Epub 2020 Jul 2.

3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg;

Adhesive properties of leukemia cells shape the degree of organ infiltration and the extent of leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important factors of progenitor cell adhesion in bone marrow (BM). Here, we report their cooperation in acute myeloid leukemia (AML) by a novel non-classical CD44-mediated way of inside-out VLA-4 activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.231944DOI Listing

Expression and clinical significance of phospholipase D1 in acute myeloid leukemia.

Hematology 2020 Dec;25(1):270-275

Department of Pathology, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, People's Republic of China.

Phospholipase D (PLD) is known to participate in several aspects of cellular processes including cell mitosis, migration, phagocytosis, and membrane vesicle trafficking. The role of PLD has been investigated in multiple cancers except hematologic malignances. We enrolled 291 patients with acute myeloid leukemia (AML) and detected PLD1 mRNA expression levels of their bone marrow samples by quantitative real-time PCR (qRT-PCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2020.1786971DOI Listing
December 2020

[Hepatolienal candidosis as a rare differential diagnosis of disseminated small parenchym lesions].

Dtsch Med Wochenschr 2020 Jul 2;145(13):912-916. Epub 2020 Jul 2.

Klinik für Diagnostische und Interventionelle Radiologie, Uniklinikum Ulm, Ulm.

History:  We report about a 17-year-old patient with the secondary malignancy of acute myeloid leukemia (AML). He developed fever of unclear origin during the hematopoietic stem cell transplantation.History We report about a 17-year-old patient with the secondary malignancy of acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1164-0043DOI Listing

Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.

Blood Adv 2020 Jul;4(13):3000-3010

Department of Hematology, University Hospital Essen, Essen, Germany.

Acute myeloid leukemia (AML) is characterized by a high relapse rate and dismal long-term overall survival which is related to persistence of leukemia-initiating cells in their niche. Different animal models of myeloid malignancies reveal how neoplastic cells alter the structural and functional characteristics of the hematopoietic stem cell niche to reinforce malignancy. Understanding and disruption of the microenvironmental interactions with AML cells are a vital need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001292DOI Listing

The expression and regulation of HOX genes and membrane proteins among different cytogenetic groups of acute myeloid leukemia.

Mol Genet Genomic Med 2020 Jul 2:e1365. Epub 2020 Jul 2.

Hubei Bioinformatics & Molecular Imaging Key Laboratory, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.

Background: The cytogenetic aberrations were considered as markers for diagnosis and prognosis in acute myeloid leukemia (AML), while the expression and regulation under different cytogenetic groups remain to be fully elucidated.

Methods: In this paper, for favorable, poor, and cytogenetically normal groups of AML patients, we performed comprehensive bioinformatics analyses including identifying differentially expressed genes (DEGs) and microRNAs (miRNAs) among them, functional enrichment and regulatory networks.

Results: We found that DEGs were enriched in membrane-related processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mgg3.1365DOI Listing

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Leuk Res Rep 2020 18;14:100213. Epub 2020 Jun 18.

University Hospitals Birmingham NHS Foundation Trust, Heartlands Hospital.

Herein we present a female patient aged 61 with Philadelphia negative acute lymphoblastic leukaemia demonstrating near haploid karyotype and abnormal TP53 expression at diagnosis, who relapsed with lineage switch as Acute Monocytic Leukemia post allogeneic stem cell transplantation. Molecular analysis established that both neoplasms were derived from the same founder clone. The leukemic lineage switch phenomenon has recently re-attracted interest as mechanism of leukemic evasion post treatment with chimeric antigen receptor T-cells but there is paucity of data on its presence post allograft or following novel antibody treatments such as Inotuzumab Ozogamicin or Blinatumomab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lrr.2020.100213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317226PMC

Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.

Leuk Lymphoma 2020 Jul 1:1-2. Epub 2020 Jul 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786559DOI Listing

Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.

Cancers (Basel) 2020 Jun 29;12(7). Epub 2020 Jun 29.

Unité Mixte de Recherche (UMR)1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France.

Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the inhibition of a sterol isomerase. We hypothesize that DDA could potentiate the activity of an anticancer drug acting through a different molecular mechanism, and conducted in vitro and in vivo combination tests on AML cell lines and patient primary tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071725DOI Listing

Vitamin B6 Fuels Acute Myeloid Leukemia Growth.

Authors:
Shuai Jiang

Trends Cancer 2020 Jul 2;6(7):536-537. Epub 2020 Apr 2.

Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA. Electronic address:

Mounting evidence indicates that vitamins C and D are linked to tumor growth, but the relevance of vitamin B6 remains uncertain. In a recent study, Chen et al. demonstrate that pyridoxal kinase promotes vitamin B6 phosphorylation, producing the active form pyridoxal 5'-phosphate, which regulates two key metabolic enzymes required for acute myeloid leukemia (AML) cell growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2020.03.005DOI Listing

NPM1-mutated acute myeloid leukemia: from bench to bedside.

Blood 2020 Jul 1. Epub 2020 Jul 1.

Hematology, CREO, University of Perugia, Perugia, Italy.

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations represent the most common genetic lesion in adult AML (about one-third of cases) and act deterministically to cause the aberrant cytoplasmic delocalization of NPM1 mutants. Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2016 World Health Organization classification of hematopoietic neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004226DOI Listing

Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia.

JCO Oncol Pract 2020 Jul 1:OP2000107. Epub 2020 Jul 1.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Purpose: Patients with newly diagnosed acute myeloid leukemia (AML) are at risk of infection, including odontogenic infections, during induction chemotherapy. It is unknown whether clinical dental screening to diagnose and treat odontogenic disease in these patients can reduce the incidence of dental emergencies.

Methods: Between November 1, 2014, and December 31, 2016, we screened 147 patients with newly diagnosed AML before their admission for induction chemotherapy (n 147, "screened" group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00107DOI Listing

Long non-coding RNA LINC01268 promotes cell growth and inhibits cell apoptosis by modulating miR-217/SOS1 axis in acute myeloid leukemia.

Braz J Med Biol Res 2020 26;53(8):e9299. Epub 2020 Jun 26.

Department of Hematology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.

The aim of this study was to evaluate the pathogenic role of newly identified long non-coding (lnc)-RNA LINCO1268 in acute myeloid leukemia (AML), and investigate its therapeutic potential. The expression level of LINC01268 in AML was measured by quantitative PCR (qPCR). The viability, cell cycle progression, and apoptosis of AML cells were measured by CCK-8 assay and flow cytometry, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431X20209299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326380PMC

Poor Prognosis Biomolecular Factors Are Highly Frequent in Childhood Acute Leukemias From Oaxaca, Mexico.

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820928436

Laboratorio Juárez, Medicina de Laboratorio Clínico de Alta Especialidad, Biología Molecular e Investigación Clínica, Oaxaca de Juárez, Oaxaca, México.

Objective: To investigate the cellular and molecular epidemiology of acute leukemias in vulnerable populations of children and adolescents in Oaxaca de Juarez, Mexico.

Material And Methods: Descriptive, cross-sectional and retrospective study, conducted from 2014 to 2018 in which profiles of molecular and immunophenotypic aberrations were investigated in children and adolescents diagnosed with acute leukemia, by evaluating 28 molecular abnormalities by HemaVision-Q28 multiplex RT-PCR kit and standardized EuroFlow Immunophenotyping of bone marrow cells.

Results: We included 218 patients, with 82. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533033820928436DOI Listing

Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.

Small 2020 Jun 30:e2001890. Epub 2020 Jun 30.

Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China.

Acute myeloid leukemia (AML) is the most common adult acute leukemia with very low survival rate due to drug resistance and high relapse rate. The C-X-C chemokine receptor 4 (CXCR4) is highly expressed by AML cells, actively mediating chemoresistance and reoccurrence. Herein, a chemically synthesized CXCR4 antagonistic peptide E5 is fabricated to micelle formulation (M-E5) and applied to refractory AML mice, and its therapeutic effects and pharmacokinetics are investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.202001890DOI Listing

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation.

ACG Case Rep J 2020 May 5;7(5):e00376. Epub 2020 May 5.

Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289279PMC

A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia.

J Blood Med 2020 18;11:205-212. Epub 2020 Jun 18.

Department of Hematology and Stem Cell Transplantation, Saint Antoine Hospital, AP-HP, Paris, France.

In the last decades, adults and pediatric obesity have become a major issue in developed countries. Considerable research has been conducted in patients with acute lymphoblastic (ALL) and myeloid leukemia (AML) with the aim of correlating body mass index (BMI) and outcomes in patients undergoing chemotherapy for hematological diseases. In adults, a high BMI has been associated with increased leukemia-related mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JBM.S232655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308124PMC

Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.

Drug Des Devel Ther 2020 18;14:2413-2422. Epub 2020 Jun 18.

Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China.

Purpose: Acute myeloid leukemia (AML) is a complex malignancy characterized by the clonal expansion of immature myeloid precursors. The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity. Thus, it is promising to treat AML through combination drug therapy to reduce the adverse effects of chemotherapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S244648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308242PMC

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.

Bone Marrow Transplant 2020 Jun 30. Epub 2020 Jun 30.

Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0984-4DOI Listing